BridgeMD
A long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation and a non-comparative transplanted patient group
EU CTIS ID: 2022-502727-21-00
What this study is testing
To evaluate long-term graft failure-free survival in highly sensitised kidney transplant patients after imlifidase administration in trial 20-MedIdeS-19 (PAES) (imlifidase cohort only)
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Signed Informed Consent obtained before any trial-related procedures.
- Willingness and ability to comply with the protocol.
- Previously transplanted in the clinical trial 20-HmedIdeS-19 (PAES).
You likely can't join if
- Inability by the judgment of the investigator to participate in the trial for other reasons.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.